Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CLNN 
Clene Inc. (CLNN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: CLNN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -95.04% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 22.24M USD | Price to earnings Ratio - | 1Y Target Price 45.17 |
Price to earnings Ratio - | 1Y Target Price 45.17 | ||
Volume (30-day avg) 50552 | Beta 0.26 | 52 Weeks Range 2.57 - 9.20 | Updated Date 04/2/2025 |
52 Weeks Range 2.57 - 9.20 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.67 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-03-11 | When Before Market | Estimate -0.878 | Actual -1.3646 |
Profitability
Profit Margin - | Operating Margin (TTM) -9510.99% |
Management Effectiveness
Return on Assets (TTM) -51.92% | Return on Equity (TTM) -1738.36% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 30932169 | Price to Sales(TTM) 65.04 |
Enterprise Value 30932169 | Price to Sales(TTM) 65.04 | ||
Enterprise Value to Revenue 90.44 | Enterprise Value to EBITDA -1.13 | Shares Outstanding 8621770 | Shares Floating 5849354 |
Shares Outstanding 8621770 | Shares Floating 5849354 | ||
Percent Insiders 36.79 | Percent Institutions 18.07 |
Analyst Ratings
Rating 4.5 | Target Price 45.17 | Buy 3 | Strong Buy 3 |
Buy 3 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Clene Inc.
Company Overview
History and Background
Clene Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for neurodegenerative diseases using nanocrystalline gold (CNM-Au8) technology. Founded to address unmet needs in neurodegenerative disease treatment.
Core Business Areas
- Neurology: Development of CNM-Au8 for neurodegenerative diseases like multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and Parkinson's disease.
- Energy Metabolism: Focuses on how CNM-Au8 can improve neuronal energy metabolism and protect against oxidative stress.
- Clinical Trials: Conducting clinical trials to assess the safety and efficacy of CNM-Au8 in various neurological conditions.
Leadership and Structure
The leadership team consists of experienced executives in the biopharmaceutical industry. The company has a structured organizational framework supporting research, development, and clinical operations.
Top Products and Market Share
Key Offerings
- CNM-Au8: CNM-Au8 is Clene's lead investigational drug candidate. It is designed to improve neuronal survival and function by catalyzing metabolic reactions in the brain. No current market share data due to it being an investigational drug. Competitors include companies developing treatments for neurodegenerative diseases like Biogen and Roche.
Market Dynamics
Industry Overview
The biopharmaceutical industry focusing on neurodegenerative diseases is characterized by high unmet needs and significant market potential. Research and development are intensive, and regulatory hurdles are substantial.
Positioning
Clene Inc. is positioned as an innovator in the neurodegenerative disease space with its unique CNM-Au8 technology. Competitive advantages lie in its potential to address underlying disease mechanisms.
Total Addressable Market (TAM)
The TAM for neurodegenerative disease treatments is substantial, estimated to be billions of dollars annually. Clene Inc. is targeting specific segments within this market with unmet needs. Exact projections are dependent on trial results and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Novel CNM-Au8 technology
- Focus on neurodegenerative diseases with high unmet need
- Strong scientific team
- Proprietary manufacturing process
Weaknesses
- Clinical trial risks and regulatory hurdles
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on successful development of CNM-Au8
- Relatively small company size
Opportunities
- Positive clinical trial results leading to regulatory approval
- Partnerships with larger pharmaceutical companies
- Expansion into new neurodegenerative indications
- Growing prevalence of neurodegenerative diseases
Threats
- Failure to achieve positive clinical trial results
- Regulatory setbacks
- Competition from other companies developing neurodegenerative disease treatments
- Patent disputes
Competitors and Market Share
Key Competitors
- BIIB
- RHHBY
- TEVA
Competitive Landscape
Clene Inc. faces competition from established pharmaceutical companies with larger resources. However, its novel CNM-Au8 technology offers a unique approach to treating neurodegenerative diseases.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the clinical stage. Growth is anticipated with successful clinical trial outcomes and potential commercialization.
Future Projections: Future projections are dependent on clinical trial results and potential regulatory approvals. Analyst estimates vary depending on the perceived probability of success.
Recent Initiatives: Recent initiatives include ongoing clinical trials for CNM-Au8 in MS, ALS, and Parkinson's disease. Actively seeking partnerships to advance development and commercialization.
Summary
Clene Inc. is a clinical-stage biopharmaceutical company with a focus on neurodegenerative diseases. Its novel CNM-Au8 technology shows promise, but the company faces significant clinical trial and regulatory risks. The company's future is heavily dependent on the success of its ongoing trials. Clene needs to secure financial resources and potentially partnerships to advance CNM-Au8 to market.
Similar Companies
ALNY
Alnylam Pharmaceuticals Inc
ALNY
Alnylam Pharmaceuticals Inc
BIIB
Biogen Inc
BIIB
Biogen Inc
TEVA
Teva Pharma Industries Ltd ADR
TEVA
Teva Pharma Industries Ltd ADR
Sources and Disclaimers
Data Sources:
- Clene Inc. Investor Relations
- SEC Filings
- Industry Reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not financial advice, and investors should conduct their own due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Clene Inc.
Exchange NASDAQ | Headquaters Salt Lake City, UT, United States | ||
IPO Launch date 2020-12-31 | CEO, President & Director Mr. Robert Etherington MBA | ||
Sector Consumer Defensive | Industry Packaged Foods | Full time employees 75 | Website https://clene.com |
Full time employees 75 | Website https://clene.com | ||
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.